FDA Looks Likely To Split Decision On Mepolizumab Approval
This article was originally published in The Pink Sheet Daily
An advisory committee was nearly unanimous that GSK’s clinical program demonstrated efficacy and safety for the IL-5 inhibitor in adult patients with severe asthma, but voted no on approval in patients ages 12-17.
You may also be interested in...
FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.
The EU is pulling out all the stops to have the one-year delay to the MDR adopted before it is too late, and a crucial vote will take place on 16 April.
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.